{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"237","upperLimit":"546","value":"435"},{"groupId":"OG001","lowerLimit":"182","upperLimit":"640","value":"311"},{"comment":"The upper limit of the confidence interval cannot be estimated.","groupId":"OG002","lowerLimit":"197","upperLimit":"NA","value":"455"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"25"}],"units":"Participants"}],"description":"RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nLenalidomide: Given PO","id":"OG000","title":"Arm 1: Azacitidine/Lenalidomide"},{"description":"Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV","id":"OG001","title":"Arm 2: Azacitidine"},{"description":"Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3: Azacitidine/Vorinostat"}],"paramType":"MEDIAN","populationDescription":"Analysis includes eligible patients who had a response.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"Days"}